|1.||Mitchell, Ian: 9 articles (01/2015 - 01/2003)|
|2.||Paes, Bosco: 9 articles (01/2015 - 09/2004)|
|3.||Resch, Bernhard: 7 articles (01/2014 - 04/2008)|
|4.||Groothuis, Jessie R: 7 articles (02/2011 - 06/2002)|
|5.||Lanctôt, Krista L: 6 articles (01/2015 - 06/2002)|
|6.||Lanari, Marcello: 5 articles (01/2015 - 10/2010)|
|7.||Saji, Tsutomu: 5 articles (08/2014 - 08/2005)|
|8.||Feltes, Timothy F: 5 articles (08/2011 - 10/2003)|
|9.||Carbonell-Estrany, Xavier: 5 articles (08/2010 - 02/2003)|
|10.||Wittenberg, Wolfgang: 5 articles (02/2010 - 01/2007)|
05/01/2014 - "Palivizumab was highly effective in reducing hospitalizations due to RSV infection in Nunavut. "
01/01/2009 - "In immunocompromised patients, palivizumab has an excellent safety profile and may be beneficial in the prevention and treatment of RSV infections; however, clinical trials are needed to determine its effectiveness. "
10/01/2013 - "Passive immunization with palivizumab has proven to be safe and effective for preventing RSV hospitalization in infants at higher risk of acquiring severe RSV infection, but its expense and cumbersome monthly intravenous delivery schedule make it inaccessible to many. "
01/01/2011 - "Palivizumab is beneficial in prophylaxis for infants at high-risk for severe RSV infection although optimal indications based on cost-effectiveness considerations have not been defined. "
01/01/2009 - "This study suggests that, compared with no prophylaxis, palivizumab is cost-effective in the prevention of respiratory syncytial virus infection among high risk preterm infants."
|2.||Heart Diseases (Heart Disease)
11/01/2010 - "Palivizumab has proven efficacy for prophylaxis of respiratory syncytial virus (RSV) in infants with prematurity or congenital heart disease. "
12/01/2008 - "In spite of these factors, RSV prophylaxis using palivizumab in premature children with BPD or hemodynamically significant congenital-heart disease can be considered cost-effective in France."
10/01/2003 - "To evaluate the safety, tolerance, and efficacy of palivizumab in children with hemodynamically significant congenital heart disease (CHD). "
12/01/2000 - "(6) Given the lack of relevant trials, we do not know if palivizumab is effective in infants with immunodeficiency or congenital heart diseases. "
10/01/2015 - "This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey. "
01/01/2009 - "Performing several multiple Poisson models that also considered Palivizumab use as covariate, although the point estimates were in agreement with previous clinical trial results, we did not find in most of them a significant reduction for immunized children to be hospitalized for bronchiolitis. "
10/01/2003 - "[Potential impact and cost-efficacy of bronchiolitis prophylaxis with palivizumab in preterm infants with a gestational age of less than 33 weeks]."
12/01/2004 - "This study strongly supports the efficacy of prevention of RSV bronchiolitis by palivizumab in severely premature infants with BPD."
05/01/2015 - "A literature search up to December 2012 on the morbidity of RSV bronchiolitis in CF patients and on the safety and efficacy of palivizumab in those patients was performed. "
01/01/2009 - "We evaluated the incidence and risk factors of hospitalization for broncholitis in preterm infants (i.e., a gestational age of <36 weeks) born between 2000 and 2006, and the use and impact of Palivizumab, a monoclonal antibody that in randomized clinical trials has been shown to lessen the severity of RSV-related bronchiolitis. "
|4.||Lung Diseases (Lung Disease)
08/01/2008 - "Considering the presence of pulmonary hypoplasia in severe CDH, the routine use of monoclonal antibody for RSV (palivizumab) might be effective for patients with severe CDH in the high season of RSV, similar to the patients with chronic lung disease, although further large multicenter studies are needed to clarify this hypothesis."
10/01/2001 - "Assuming a drug efficacy of 39% in infants with chronic lung disease and 78% in infants born before 33 weeks' gestation with no chronic lung disease, $121,147 of these costs could have been averted if palivizumab had been used. "
01/01/2014 - "From April 2011 to March 2013, we enrolled infants born at ≤28 weeks gestation and infants born at ≤35 weeks gestation with chronic lung disease (CLD) who received palivizumab prophylaxis as study group and followed up for 12 months. "
12/01/2013 - "This model adequately described observed palivizumab concentrations from the different pediatric studies and was subsequently used to simulate expected palivizumab serum concentrations for 3 monthly doses compared with 5 monthly doses in children younger than 24 months with chronic lung disease of prematurity and infants younger than 6 months postnatal age who were born at ≤ 35 weeks gestational age. "
08/01/2012 - "Excluded from the study were 167 subjects with chronic lung disease who had received palivizumab prophylaxis and 38 subjects who were not tested for RSV. "
03/01/2002 - "Palivizumab prophylaxis has appeared to be safe and effective for prevention of serious RSV illness in premature children and those with bronchopulmonary dysplasia."
03/01/2007 - "The present study was designed to determine the efficacy of administration of palivizumab to preterm infants with gestational age (GA) < or = 30 weeks without bronchopulmonary dysplasia (BPD). "
12/01/2004 - "The efficacy of palivizumab prophylaxis after bronchopulmonary dysplasia (BPD) has been demonstrated in a single placebo-controlled trial. "
12/01/2000 - "(5) A double-blind trial in 1 502 infants either aged less than 6 months and born prematurely (35 weeks of gestation or earlier), or aged under 2 years with a history of bronchopulmonary dysplasia, has shown that, relative to a placebo, palivizumab reduces the hospitalisation rates by 5% in absolute values. "
01/01/2014 - "Relationships were evaluated between disease severity and gestational age, age at enrollment, age at RSVH, presence of bronchopulmonary dysplasia, sex, race, multiple birth, household smoking, daycare attendance, sibling(s), family history of atopy, duration between most recent palivizumab dose and RSVH, and palivizumab level at RSVH. "
|3.||human MEDI-524 monoclonal antibody (Numax)
|6.||Nitrous Oxide (Laughing Gas)
|8.||respiratory syncytial virus immune globulin intravenous
|3.||Transplantation (Transplant Recipients)
|5.||Artificial Respiration (Mechanical Ventilation)